Health-Chem Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HCLC research report →
Company
Health-Chem Corporation, through its subsidiary, Transderm Laboratories Corporation, engages in the research, development, manufacture, and marketing of transdermal drug delivery systems in the United States. It offers transdermal nitroglycerin patches used for transdermal relief of the vascular and cardiovascular symptoms related to angina pectoris (chest pain). The company also conducts research and development activities for third parties on a contract basis.
- CEO
- Ronald J. Burghauser
- IPO
- 1972
- Employees
- 55
- HQ
- Emigsville, PA, US
Price Chart
Valuation
- Market Cap
- $73.98K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- -0.00
- EV/EBITDA
- -12.55
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 9.81%
- Op Margin
- 44.51%
- Net Margin
- -27.88%
- ROE
- 10.51%
- ROIC
- -31.87%
Growth & Income
- Revenue
- $5.94M · -21.70%
- Net Income
- $-1,656,000 · 33.23%
- EPS
- $-0.14 · 36.36%
- Op Income
- $2.64M
- FCF YoY
- 216.33%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -26.02
- Avg Volume
- 0
Get TickerSpark's AI analysis on HCLC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HCLC Coverage
We haven't published any research on HCLC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HCLC Report →